Inicio › Cáncer de pulmón de células pequeñas › Texas
Ensayos clínicos de Cáncer de pulmón de células pequeñas en Texas
41 estudios sobre Cáncer de pulmón de células pequeñas buscan participantes en Texas.
Ciudades en Texas
- Houston26 estudios
- Dallas13 estudios
- San Antonio11 estudios
- Austin7 estudios
- Irving6 estudios
- Tyler5 estudios
Texto oficial del estudio (inglés)
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07189871Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- Texas Oncology - Northeast Texas, Allen
- Texas Oncology - DFW, Arlington
- Texas Oncology - DFW, Arlington
- y 33 más
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07226999A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Oncology, Austin
- UT Southwestern, Dallas
ReclutandoFase 1
Edades de 19 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06586957DESTINY-PANTUMOUR04
- Research Site, Dallas
ReclutandoEstudio observacional
Edades de 18 a 130 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07124000A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NEXT Dallas, Irving
- NEXT Oncology, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT03460977Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06047379A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- The University of Texas MD Anderson Cancer Center /ID# 277929, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07155174A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- The University of Texas MD Anderson Cancer Center /ID# 280070, Houston
- Texas Oncology - Northeast Texas /ID# 280642, Tyler
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07365241A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Next Oncology - Austin, Austin
- Next Oncology - Houston, Houston
- Next Oncology - Dallas, Irving
- y 1 más
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07488676Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT05983432A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Site 1005, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07407933The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- New Experimental Therapeutics - NEXT Oncology, Austin
- Texas Oncology, Bedford
- UT Southwest Simmons Cancer Center, Dallas
- y 2 más
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT04585750A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Texas Oncology - Central South, Austin
- University of Texas Southwestern Medical Center/Clinical Research Department, Dallas
- Texas Oncology - West Texas, Odessa
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT07218146A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Texas Oncology - Central/South Texas, Austin
- Texas Oncology - Northeast Texas, Tyler
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT06646276A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT07564401AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Dallas
- Avenzo Therapeutics Recruiting Site, Houston
- Avenzo Therapeutics Recruiting Site, San Antonio
ReclutandoFase 1/2
Edades de 18 a 75 · Todos los sexos · Actualizado el 4 sept 2026 · NCT07038343Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- The University of Texas MD Anderson Cancer Center, Houston
- Texas Oncology Cancer Center, Sugar Land
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 sept 2026 · NCT06712355Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- MD Anderson Cancer Center Uni of Te, Houston
ReclutandoFase 1/2
Edades de 18 a 100 · Todos los sexos · Actualizado el 27 ago 2026 · NCT06726148A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Texas Oncology - DFW, Dallas
- MD Anderson Cancer Center, Houston
- Texas Oncology - Northeast, Tyler
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 ago 2026 · NCT06892548A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT07488923A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- University of Texas Southwestern Medical Center, Dallas
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT06095505A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The University of Texas, MD Anderson Cancer Center, Houston
- UT Health Mays Cancer Center, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 ago 2026 · NCT05592626A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 ago 2026 · NCT06242470A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Houston Methodist Cancer Center, Houston
- University of Texas Md Anderson Cancer Center, Houston
- Texas Oncology, P.A. - Tyler, Tyler
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ago 2026 · NCT06203210A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ago 2026 · NCT07749586A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Dallas, Irving
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT06131840A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Mays Cancer Center / University of Texas, San Antonio, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 jul 2026 · NCT05652686A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- The University of Texas MD Anderson Cancer Center, Houston
- Oncology Consultants, PA- Houston, Houston
- Next Oncology Dallas, Irving
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 jul 2026 · NCT07174583Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 jun 2026 · NCT06598306A Study of LY4175408 in Participants With Advanced Cancer
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jun 2026 · NCT07046923Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- START Dallas, Fort Worth
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jun 2026 · NCT07517198AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
- NEXT Oncology, Irving
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jun 2026 · NCT07454642Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
- NEXT Oncology Austin, Austin
- NEXT Oncology San Antonio, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 abr 2026 · NCT07424547Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- M D Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 mar 2026 · NCT06769126Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 mar 2026 · NCT06681220Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- NEXT Oncology - Dallas, Dallas
- START San Antonio, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 feb 2026 · NCT07030257JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Mary Crowley Cancer Research, Dallas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 ene 2026 · NCT05490472VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- The University of Texas MD Anderson Cancer Center (site 127), Houston
ReclutandoFase 1/2
Edades de 18 a 80 · Todos los sexos · Actualizado el 11 dic 2025 · NCT03556228A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 135, Austin
- Research Site 120, Dallas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 nov 2025 · NCT05914116A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2025 · NCT06805825De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.